Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Systems to Raise $7.7M in Private Placement

NEW YORK, Sept. 8 (GenomeWeb News) - Proteome Systems plans to raise approximately AU$10 million ($7.7 million) through a private placement to institutional and professional investors in the UK, US, and Australia, the Australian company said today.

 

In the placement, which still requires shareholder approval, Proteome Systems will issue up to 33.33 million fully paid ordinary shares to the investors at a price of AU$.30 per share.

 

The company expects net proceeds of approximately AU$9.75 million from the placement, allowing it to further develop its diagnostics and therapeutics business. In particular, Proteome Systems plans to accelerate the development of its diagnostic for active tuberculosis and to start clinical development of one of its lead scavenger drug compounds as a topical treatment for a range of dermatological diseases.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.